1. Home
  2. NPKI vs CRGX Comparison

NPKI vs CRGX Comparison

Compare NPKI & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NPKI
  • CRGX
  • Stock Information
  • Founded
  • NPKI 1932
  • CRGX 2021
  • Country
  • NPKI United States
  • CRGX United States
  • Employees
  • NPKI N/A
  • CRGX N/A
  • Industry
  • NPKI Metal Fabrications
  • CRGX
  • Sector
  • NPKI Industrials
  • CRGX
  • Exchange
  • NPKI Nasdaq
  • CRGX Nasdaq
  • Market Cap
  • NPKI 722.7M
  • CRGX 190.0M
  • IPO Year
  • NPKI N/A
  • CRGX 2023
  • Fundamental
  • Price
  • NPKI $8.82
  • CRGX $4.46
  • Analyst Decision
  • NPKI Strong Buy
  • CRGX Hold
  • Analyst Count
  • NPKI 1
  • CRGX 7
  • Target Price
  • NPKI $12.00
  • CRGX $4.67
  • AVG Volume (30 Days)
  • NPKI 951.9K
  • CRGX 502.9K
  • Earning Date
  • NPKI 08-04-2025
  • CRGX 08-11-2025
  • Dividend Yield
  • NPKI N/A
  • CRGX N/A
  • EPS Growth
  • NPKI N/A
  • CRGX N/A
  • EPS
  • NPKI N/A
  • CRGX N/A
  • Revenue
  • NPKI $233,299,000.00
  • CRGX N/A
  • Revenue This Year
  • NPKI $15.28
  • CRGX $57.81
  • Revenue Next Year
  • NPKI $9.62
  • CRGX N/A
  • P/E Ratio
  • NPKI $18.12
  • CRGX N/A
  • Revenue Growth
  • NPKI 312.30
  • CRGX N/A
  • 52 Week Low
  • NPKI $4.76
  • CRGX $3.00
  • 52 Week High
  • NPKI $8.88
  • CRGX $25.45
  • Technical
  • Relative Strength Index (RSI)
  • NPKI N/A
  • CRGX 57.89
  • Support Level
  • NPKI N/A
  • CRGX $4.09
  • Resistance Level
  • NPKI N/A
  • CRGX $4.51
  • Average True Range (ATR)
  • NPKI 0.00
  • CRGX 0.18
  • MACD
  • NPKI 0.00
  • CRGX 0.00
  • Stochastic Oscillator
  • NPKI 0.00
  • CRGX 77.18

About NPKI NPK International Inc. Common Stock

NPK International Inc is a temporary worksite access solutions company that manufactures, sells, and rents recyclable composite matting products, along with a full suite of services, including planning, logistics, and site restoration. The company generates majority of revenue from the rental of recyclable composite matting systems, along with related site construction and services to customers in various markets including power transmission, oil and natural gas exploration and production, pipeline, renewable energy, petrochemical, construction and other industries within the United States and United Kingdom.

About CRGX CARGO Therapeutics Inc.

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.

Share on Social Networks: